pCR Rates in Patients With Bilateral Breast Cancer After Neoadjuvant Anthracycline-Taxane Based-Chemotherapy. A Retrospective Pooled Analysis of Individual Patient Data From Four German Neoadjuvant Trials

Researchers from Germany noted that patients with bilateral breast cancer (BBC) are usually excluded from participating in clinical trials and, thus, little is known about the response rates and outcomes associated with neoadjuvant chemotherapy compared with patients with unilateral BC (UBC). They concluded that patients with BBC had lower pCR rates and a lower DFS than patients with UBC.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.